SuperworthPalvella Therapeutics revenue PVLA
Sales by quarter and over the last twelve months, from 2013.
- Last 12 months, to Sep 30, 2024
- $1.4M
- Latest quarter, Q3 FY24
- $0
- −100% on a year earlier
- Fiscal year 2023
- $42.8M
- +65% on the year before
Palvella Therapeutics' revenue was $1.4M over the twelve months to Sep 30, 2024, down 97% on a year earlier.
In its latest quarter, Q3 FY24, it was $0, down 100% on the same quarter a year before.
Over the five fiscal years to FY2023 it grew 8% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2023 | $42.8M | +65% |
| FY2022 | $25.9M | −18% |
| FY2021 | $31.4M | +7% |
| FY2020 | $29.3M | −37% |
| FY2019 | $46.3M | +59% |
| FY2018 | $29.1M | +15% |
| FY2017 | $25.3M | +333% |
| FY2016 | $5.8M | +99% |
| FY2015 | $2.9M | +42% |
| FY2014 | $2.1M | −61% |
| FY2014 | $5.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY24 | $0 | −100% | $1.4M | |
| Q2 FY24 | $0 | −100% | $20.9M | |
| Q1 FY24 | $53K | −97% | $40.9M | |
| Q4 FY23 | $1.3M | −78% | $42.8M | |
| Q3 FY23 | $19.5M | +264% | $47.4M | |
| Q2 FY23 | $20.1M | +442% | $33.2M | |
| Q1 FY23 | $1.9M | −82% | $16.9M | |
| Q4 FY22 | $5.8M | −31% | $25.9M | |
| Q3 FY22 | $5.4M | +32% | $28.5M | |
| Q2 FY22 | $3.7M | +13% | $27.2M | |
| Q1 FY22 | $11M | −30% | $26.8M | |
| Q4 FY21 | $8.4M | +350% | $31.4M |
Against its peers
Companies in Drug Manufacturers - General nearest Palvella Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| PVLAPalvella Therapeutics | n/m | |
| ANIPANI Pharmaceuticals | $978.4M | +31% a year |
| PAHCPhibro Animal Health | $1.5B | +17% a year |
| HRMYHarmony Biosciences | $959.9M | +24% a year |
| ANABAnaptysbio | n/m | |
| PCRXPacira BioSciences | $746.2M | +6% a year |
| PBHPrestige Consumer Healthcare | $1.1B | −1% a year |
| OMEROmeros | n/m | |
| NRIXNurix Therapeutics | $701.9M | |
| AMPHAmphastar Pharmaceuticals | $730M | +1% a year |
| OGNOrganon | $6.1B | −2% a year |
| Peer median | $969.1M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Palvella Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.